Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

The third phase, inter-critical gout, is a period between acute attacks when the patient is symptom-free. Finally, chronic ...

A swollen toe is a key sign of gout, a type of arthritis. But your ankle is at risk too. Here's what gout symptoms in an ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

The report Gout Therapeutics Market Size, Share, Trends & Analysis Report, By Drug Class (Urate-Lowering Agents, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs [NSAIDs], Colchicine); By Disease ...

"We are excited and very pleased with the outcome of our Phase 2b clinical study in this difficult-to-treat population of refractory gout patients" says Dr. Bing Li, Shanton's CEO ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...